AMDHD1

Across TCGA pan-cancer cohorts, AMDHD1 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated AMDHD1 data layer compared with 20 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher AMDHD1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated AMDHD1 expression acts as an unfavorable survival marker, although some lineages such as SKCM and SCLC show a favorable association.

BLCA, SKCM, and SCLC are the cancer types where AMDHD1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	IV	0.130	0.599	.002	12	view →
SKCM	DFS	Median	All	0.690	0.199	.021	6	view →
SCLC	OS	Median	III,IV	1.000	0.413	.046	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

AMDHD1–BLCA (OS)

Open the BLCA breakdown →